 | • レポートコード：MRC2303H002 • 出版社/出版日：360iResearch / 2022年10月11日 • レポート形態：英語、PDF、239ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の当調査レポートでは、2021年に1,691.23百万ドルであった世界の全身性エリテマトーデス（SLE）市場規模が2022年に1,858.15百万ドルとなり、今後は年平均10.12％成長して2027年までに3,016.59百万ドルに達すると予測しています。当書は、全身性エリテマトーデス（SLE）の世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、薬剤種類別（抗マラリア薬、生物製剤、細胞傷害性＆免疫抑制薬、非ステロイド性抗炎症薬（NSAIDS）、炎症誘発性＆サイトカイン阻害剤）分析、送達方法別（静脈、口腔内、皮下、局所）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報など、以下の構成でまとめております。なお、当書には、Abbvie, Inc.、Amgen Inc.、Anthera Pharmaceuticals、AstraZeneca Plc、Aurinia Pharmaceuticals Inc、bioMérieux SA、Biotest AG、Boston Pharmaceuticals、Bristol-Myers Squibb Company、Eli Lilly and Companyなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の全身性エリテマトーデス（SLE）市場規模：薬剤種類別 - 抗マラリア薬の市場規模 - 生物製剤の市場規模 - 細胞傷害性＆免疫抑制薬の市場規模 - 非ステロイド性抗炎症薬（NSAIDS）の市場規模 - 炎症誘発性＆サイトカイン阻害剤の市場規模 ・世界の全身性エリテマトーデス（SLE）市場規模：送達方法別 - 静脈送達の市場規模 - 口腔内送達の市場規模 - 皮下送達の市場規模 - 局所送達の市場規模 ・世界の全身性エリテマトーデス（SLE）市場規模：地域別 - 南北アメリカの全身性エリテマトーデス（SLE）市場規模 アメリカの全身性エリテマトーデス（SLE）市場規模 カナダの全身性エリテマトーデス（SLE）市場規模 ブラジルの全身性エリテマトーデス（SLE）市場規模 ... - アジア太平洋の全身性エリテマトーデス（SLE）市場規模 日本の全身性エリテマトーデス（SLE）市場規模 中国の全身性エリテマトーデス（SLE）市場規模 インドの全身性エリテマトーデス（SLE）市場規模 韓国の全身性エリテマトーデス（SLE）市場規模 台湾の全身性エリテマトーデス（SLE）市場規模 ... - ヨーロッパ/中東/アフリカの全身性エリテマトーデス（SLE）市場規模 イギリスの全身性エリテマトーデス（SLE）市場規模 ドイツの全身性エリテマトーデス（SLE）市場規模 フランスの全身性エリテマトーデス（SLE）市場規模 ロシアの全身性エリテマトーデス（SLE）市場規模 ... - その他地域の全身性エリテマトーデス（SLE）市場規模 ・競争状況 ・企業情報 |
The Global Systemic Lupus Erythematosus Market size was estimated at USD 1,691.23 million in 2021 and expected to reach USD 1,858.15 million in 2022, and is projected to grow at a CAGR 10.12% to reach USD 3,016.59 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Systemic Lupus Erythematosus to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Drug Type, the market was studied across Antimalarial Drugs, Biologics, Cytotoxic & Immunosuppressive Drugs, Immunosuppressive & Cytotoxic Drugs O T-Cell Modulators, Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), o B-Cell modulators, and Pro-Inflammatory & Cytokine Inhibitors. The Antimalarial Drugs is further studied across Chloroquine and Hydrochloroquine. The Biologics is further studied across Approved Biologics for Treating SLE and Biologics Used Off-Label. The Approved Biologics for Treating SLE is further studied across B-Cell Targeted Therapy and Blys-Blockers (Belimumab). The Cytotoxic & Immunosuppressive Drugs is further studied across Cyclophosphamide, Cyclosporine, Methotrexate, and Mycophenolate Mofetil o Tacrolimus.
Based on Mode of Delivery, the market was studied across Intravenous, Oral, Subcutaneous, and Topical.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Systemic Lupus Erythematosus market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Systemic Lupus Erythematosus Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Systemic Lupus Erythematosus Market, including Abbvie, Inc., Amgen Inc., Anthera Pharmaceuticals, AstraZeneca Plc, Aurinia Pharmaceuticals Inc, bioMérieux SA, Biotest AG, Boston Pharmaceuticals, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline Plc, Hoffmann-LA-Roche Ltd., ImmuPharma PLC,, Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer, Inc., RemeGen Co., Ltd., Sandoz International GmbH,, Sanofi, Trinity Biotech, UCB SA, Xencor, Inc., and Zydus Cadila,.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Systemic Lupus Erythematosus Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Systemic Lupus Erythematosus Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Systemic Lupus Erythematosus Market?
4. What is the competitive strategic window for opportunities in the Global Systemic Lupus Erythematosus Market?
5. What are the technology trends and regulatory frameworks in the Global Systemic Lupus Erythematosus Market?
6. What is the market share of the leading vendors in the Global Systemic Lupus Erythematosus Market?
7. What modes and strategic moves are considered suitable for entering the Global Systemic Lupus Erythematosus Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of systemic lupus erythematosus worldwide
5.1.1.2. Rising awareness of inflammatory autoimmune diseases and treatment
5.1.1.3. Improvement in healthcare infrastructure and lupus clinics
5.1.2. Restraints
5.1.2.1. High cost of treatment and lack of infrastructure in low-income countries
5.1.3. Opportunities
5.1.3.1. Significant funding and investment for lupus research activities
5.1.3.2. Advancement in treatment technologie and launch of new products
5.1.4. Challenges
5.1.4.1. Complications in treatment and other difficulties in managing SLE
5.2. Cumulative Impact of COVID-19
6. Systemic Lupus Erythematosus Market, by Drug Type
6.1. Introduction
6.2. Antimalarial Drugs
6.3.1. Chloroquine
6.3.2. Hydrochloroquine
6.3. Biologics
6.4.1. Approved Biologics for Treating SLE
6.4.2.1. B-Cell Targeted Therapy
6.4.2.2. Blys-Blockers (Belimumab)
6.4.2. Biologics Used Off-Label
6.4. Cytotoxic & Immunosuppressive Drugs
6.5.1. Cyclophosphamide
6.5.2. Cyclosporine
6.5.3. Methotrexate
6.5.4. Mycophenolate Mofetil o Tacrolimus
6.5. Immunosuppressive & Cytotoxic Drugs O T-Cell Modulators
6.6. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
6.7. o B-Cell modulators
6.8. Pro-Inflammatory & Cytokine Inhibitors
7. Systemic Lupus Erythematosus Market, by Mode of Delivery
7.1. Introduction
7.2. Intravenous
7.3. Oral
7.4. Subcutaneous
7.5. Topical
8. Americas Systemic Lupus Erythematosus Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Systemic Lupus Erythematosus Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Systemic Lupus Erythematosus Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis, By Key Player
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion
12. Company Usability Profiles
12.1. Abbvie, Inc.
12.1.1. Business Overview
12.1.2. Key Executives
12.1.3. Product & Services
12.2. Amgen Inc.
12.2.1. Business Overview
12.2.2. Key Executives
12.2.3. Product & Services
12.3. Anthera Pharmaceuticals
12.3.1. Business Overview
12.3.2. Key Executives
12.3.3. Product & Services
12.4. AstraZeneca Plc
12.4.1. Business Overview
12.4.2. Key Executives
12.4.3. Product & Services
12.5. Aurinia Pharmaceuticals Inc
12.5.1. Business Overview
12.5.2. Key Executives
12.5.3. Product & Services
12.6. bioMérieux SA
12.6.1. Business Overview
12.6.2. Key Executives
12.6.3. Product & Services
12.7. Biotest AG
12.7.1. Business Overview
12.7.2. Key Executives
12.7.3. Product & Services
12.8. Boston Pharmaceuticals
12.8.1. Business Overview
12.8.2. Key Executives
12.8.3. Product & Services
12.9. Bristol-Myers Squibb Company
12.9.1. Business Overview
12.9.2. Key Executives
12.9.3. Product & Services
12.10. Eli Lilly and Company
12.10.1. Business Overview
12.10.2. Key Executives
12.10.3. Product & Services
12.11. GlaxoSmithKline Plc
12.11.1. Business Overview
12.11.2. Key Executives
12.11.3. Product & Services
12.12. Hoffmann-LA-Roche Ltd.
12.12.1. Business Overview
12.12.2. Key Executives
12.12.3. Product & Services
12.13. ImmuPharma PLC,
12.13.1. Business Overview
12.13.2. Key Executives
12.13.3. Product & Services
12.14. Merck & Co., Inc.
12.14.1. Business Overview
12.14.2. Key Executives
12.14.3. Product & Services
12.15. Mylan N.V.
12.15.1. Business Overview
12.15.2. Key Executives
12.15.3. Product & Services
12.16. Novartis AG
12.16.1. Business Overview
12.16.2. Key Executives
12.16.3. Product & Services
12.17. Pfizer, Inc.
12.17.1. Business Overview
12.17.2. Key Executives
12.17.3. Product & Services
12.18. RemeGen Co., Ltd.
12.18.1. Business Overview
12.18.2. Key Executives
12.18.3. Product & Services
12.19. Sandoz International GmbH,
12.19.1. Business Overview
12.19.2. Key Executives
12.19.3. Product & Services
12.20. Sanofi
12.20.1. Business Overview
12.20.2. Key Executives
12.20.3. Product & Services
12.21. Trinity Biotech
12.21.1. Business Overview
12.21.2. Key Executives
12.21.3. Product & Services
12.22. UCB SA
12.22.1. Business Overview
12.22.2. Key Executives
12.22.3. Product & Services
12.23. Xencor, Inc.
12.23.1. Business Overview
12.23.2. Key Executives
12.23.3. Product & Services
12.24. Zydus Cadila,
12.24.1. Business Overview
12.24.2. Key Executives
12.24.3. Product & Services
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing